Treosulfan is an alkylating agent increasingly used prior to haematopoietic stem cell transplantation. The aim of this study was to develop a population pharmacokinetic (PK) model of treosulfan in paediatric haematopoietic stem cell transplantation recipients and to explore the effect of potential covariates on treosulfan PK. Also, a limited sampling model (LSM) will be developed to accurately predict treosulfan exposure suitable for a therapeutic drug monitoring setting. Samples taken at 1.5, 4 and 7 hours after start of infusion resulted in the best limited sampling strategy.
Treosulfan is an alkylating agent with both myeloablative and immunosuppressive properties. 1 In the last decade, treosulfan is increasingly being used in conditioning regimens prior to haematopoietic stem cell transplantation (HSCT) in children with both malignant and nonmalignant disorders. It has been shown to be effective and has a relatively mild toxicity profile. [2] [3] [4] [5] [6] [7] The most commonly reported toxicities are skin, mucosal, gastrointestinal and hepatic toxicity. 4, [6] [7] [8] Treosulfan is an analogue of busulfan, from which it differs for 2 hydroxyl groups leading to a somewhat different mechanism of action. 9 Treosulfan is a prodrug and is nonenzymatically, pH-dependently converted into monoepoxide and diepoxide derivatives ((S,S)-EDBM and (S,S)-DEB, respectively). 10 These metabolites are thought to be responsible for DNA alkylation, interstrand DNA crosslinking, chromosomal aberration and, finally, induction of apoptosis.
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To date, only a few papers have described the clinical pharmacokinetics (PK) of treosulfan in children, often based on small sample size datasets. [12] [13] [14] [15] [16] [17] [18] Three population PK models in children have been published, including 1 by our own group (see Table S1 ). However, the sample size of 2 of the 3 studies was limited and, besides bodyweight (BW), no significant covariates could be identified to explain interindividual variability in PK. 12, 16, 17 Also, the inclusion of infants (children aged <2 years) was limited; a population particularly of interest because variability and total exposure seems especially high in this subgroup. 13, 18 To perform PK-guided dosing and to accurately establish the exposure, intensive blood sampling is required. This may be laborious for both patients and staff employing PK-guided dosing in daily practice.
In a pilot study, we reported that a limited sampling model (LSM) based on PK data from 20 paediatric patients based was capable of accurately predicting the area under the concentration-time curve from zero to infinity (AUC 0-∞) , with a model-based approach, requiring only 2 blood samples. 17 The primary aim of the current study is to develop a population PK model of treosulfan in paediatric HSCT recipients with improved predictive performance compared to previously published models using a comprehensive multi-institutional dataset. The secondary aim is to identify patient-related factors that may explain PK variability by means of a covariate analysis. Finally, an LSM will be developed to accurately estimate treosulfan systemic exposure suitable for a therapeutic drug monitoring (TDM) setting.
2 | METHODS
| Patient population
All paediatric patients who had participated in a prospective, observa- day, 3-hour infusion). Patients who underwent a second transplantation (n = 7) in which treosulfan was also part of the conditioning regimen were included twice in the analysis. Samples were taken at first and second transplantation. Because the time between first and second transplantation was more than several months, these results were considered as distinct individuals.
| Sampling and analysis
For treosulfan PK assessment, blood samples were collected in serum tubes (BD Vacutainer Plus plastic serum tube) on day 1. In patients who gave additional consent, blood samples were also collected on day 3 to determine intrapatient variability. Samples were collected at 1.5, 3.5, 4, 5, 7 and 9 hours after start of infusion (extensive sampling)
or at 4 and 7 hours after start of infusion (limited sampling). Samples were centrifuged as soon as possible (i.e. within 5 hours), and serum stored at −20°C. A validated reversed-phase high-pressure liquid chromatography using ultraviolet detection was used to determine treosulfan concentration in serum, as previously reported. 17 Briefly, treosulfan and the internal standard busulfan were made detectable through derivatization with sodium diethyldithiocarbamate. Linearity was established up to 500 mg/L with a lower limit of quantification of 6.8 mg/L. Accuracy of quality control samples was within the 90-110% limit. The intraday imprecision, expressed as coefficient of
What is already known about this subject
• Various population pharmacokinetic models of treosulfan have been published, including 3 in paediatric patients.
However, these were limited by a small sample size and the extent of exploration of possible covariates to explain interpatient variability.
What this study adds variation (CV%), ranged from 2.0 to 3.3% and interday imprecision ranged from 2.1 to 2.8%. 
| Pharmacokinetic modelling

| Base model
Initially, a base model was developed without covariates. Plots of observed concentration-time data of treosulfan were examined.
One-, 2-and 3-compartmental PK models with first-order elimination were compared to find the optimal fit for the concentration-time data.
Interindividual variability (IIV) was assumed to follow a log-normal distribution and was implemented in the model as follows ( Equation 1):
where P i is the PK parameter of i th individual, P pop is the population mean value of the parameters and η i is a normally distributed random value with mean zero and variance ω 2 . In 24 patients, interoccasion variability could be evaluated and implemented similarly (Equation 2) with each dose and subsequent sampling defined as a separate occasion.
A proportional error model and a combined proportional and additive error model were examined to describe the residual error. Eventually, a proportional error model was implemented as follows ( Equation 3):
where Y ij is the j th measured concentration in the i th subject, Y PREDij is the predicted concentration based on the model and εxp proportional is the proportional error component.
Four of 410 (1%) serum concentration time points were below the lower limit of quantification. These measurements (actual values) were included in the dataset as proposed by Hecht et al. 19 
| Covariate analysis
The parameter values were standardised for a BW of 70 kg and allometrically scaled (Equation 4):
where F size is the fractional difference in allometrically scaled size compared with a 70 kg individual. When scaling clearance (Cl) and intercompartmental clearance (Q) α is fixed to 0.75 and for volume of distribution of the central (V1) and peripheral compartment (V2) α is fixed to 1. 20 Furthermore, a sigmoid E max model was used to describe the maturation of treosulfan Cl on postmenstrual age (PMA) as follows ( Equation 5):
where F mat is the fraction of adult treosulfan clearance value, TM 50 is the PMA at which maturation is 50% of the adult value, and the Hill coefficient is associated with the slope of the developmental profile. 21 PMA was estimated by adding a gestational age of 40 weeks to postnatal age.
Total clearance (Cl tot ) could then be described as follows (Equation 6):
where Cl pop is the overall population value of parameter. A similar model was used for Q.
Other potential covariates were chosen based on biological or physiological plausibility and clinical relevance. Assessed covariates included: sex, underlying disease, conditioning regimen, haemoglobin, haematocrit, serum albumin and estimated glomerular filtration rate (eGFR) as a measure of renal function. This was calculated using the revised Schwartz formula (see Data S1) and, to avoid implausibly high eGFR values, was capped at 120 mL/min/1.73 m 2.22 There were no missing covariate values. All preselected covariate relationships were used for a systematic stepwise covariate modelling, with stepwise forward inclusion and backward deletion. 23 In the forward inclusion and backward deletion, the levels of statistical significance were set at P < .05 and P < .01, respectively, corresponding to differences in the NONMEM objective function value (OFV) of 3.84 and 6.64, respectively (1 degree of freedom). A covariate effect was only maintained in the model if the inclusion resulted in reduction of random variability of the PK parameter and improved model fit. In addition, the previously published models of Ten Brink et al., 17 Danielak et al. 12 and Mohanan et al. 16 were compared with the final model to show their ability to describe the current extensive treosulfan PK dataset. The difference in predictive performance was
| Final model evaluation
shown by means of comparing the prediction-corrected VPCs of the different models.
| Simulations to individualize dosing
Based on our final model, individual treosulfan doses were estimated to target an AUC 0-∞ of 1650 mg*h/L, the daily median of treosulfan AUC 0-∞ in patients receiving the most common dose of 14 g/m 2 .
Bayesian PK parameter estimates were obtained by posthoc estimation in NONMEM. AUC 0-∞ was then calculated as:
where F is equal to 1.
Clinical covariates were based on the 5 th , 50 th and 95 th percentile estimates of weight per age for boys as provided by the CDC standard growth charts for infants and children. 25 2.8 | LSM
| Patients and data collection
Thirty-five full PK profiles from 28 different patients were used to find the optimal LSM for treosulfan. These full PK profiles consisted of 6 blood samples collected over 9 hours (1.5, 3.5, 4, 5, 7 and 9 hours after start of a 3-hour infusion).
| PK and statistical analysis
True exposure (AUC full0-∞ ) was calculated from all measured concentration-time points using posthoc estimation in NONMEM with the final model ((DOSE *F1)/Cl). LSM-predicted AUC (AUC pred0-∞ ) was calculated by selecting several concentration-time points and combinations of time points. Bias and imprecision were calculated to assess the performance of the different LSMs according to the guidelines proposed by Sheiner and Beal. 26 Formulas can be found in Data S1. A Pearson correlation coefficient test was performed to determine the correlation between AUC full0-∞ and AUC pred0-∞ .
| Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMA-COLOGY, 27 and are permanently achieved in the Concise Guide to PHARMACOLOGY 2017/2018.
3 | RESULTS
| Patients
A total of 91 paediatric patients were included in this study; 58 were male and 33 female. Patient characteristics are summarized in Table 1 .
Median age was 4.3 years (range 0.1-18.2) and median BW was Table 2 .
| Comparison with previously published population PK models
Our model accounted for age and size differences over a wide age range in children (1 month-18 years). To evaluate the prediction accuracy in children, we performed prediction-corrected VPCs with the previously published treosulfan PK models ( Figure 4B , C and D) build on paediatric data. 12, 16, 17 The prediction-corrected VPCs show that all 3 models show poor predictions and are not able to properly describe the current dataset. 
| Simulations to individualize dosing
The derived population PK parameters from our model were used to calculate the required treosulfan dose to reach an AUC 0-∞ of 1650 mg*h/L (median estimated AUC 0-∞ in our cohort) for a set of virtual patients (normal weight and age range). In Table 3 , the treosulfan dose per day required to target an AUC 0-∞ of 1650 mg*h/L can be found for each age category for the 3 different corresponding normal Figure 5A ). Figure 5B shows the absolute treosulfan dose, increasing with age and weight, but with a steeper slope in the beginning accounting for maturation.
| LSM
The results of the LSM are shown in Table 4 
| DISCUSSION
In this study, the population PK of treosulfan in paediatric HSCT recipients was best described by a 2-compartment model. Allometric scaling of all parameters using BW and the addition of a maturation function using PMA was found to best account for differences in size and age. Other covariates such as sex, underlying disease, conditioning regimen, haematocrit and serum albumin did not significantly influence treosulfan PK. eGFR seems to influence treosulfan PK, because it is known from literature that up to 39% of treosulfan is excreted via the kidneys in unchanged form. [28] [29] [30] However, addition of this covariate led to an increased IIV and the prediction-corrected VPC worsened compared to the model with BW and maturation of clearance only. Therefore, we ultimately chose not to include this covariate in the final model. In our dataset, only a few patients had an eGFR below 60 mL/min/1.73 m 2 (n = 5). It is likely that this number might be insufficient to establish this potential relationship accurately.
Danielak et al. also studied covariates, but only weight and sex were examined with weight being a significant covariate. 12 Mohanan Standardizing to the median weight might be more appropriate, because standardizing to a weight outside the observed weight range can increase uncertainty of parameter estimates. 31 By contrast,
comparison with other models is more difficult when standardizing to the median weight, so in the final model the PK parameters were standardized to 70 kg. As we compared the prediction-corrected VPCs of the current model vs the models of Ten Brink et al.., 17 Danielak et al. 12 and Mohanan et al., 16 it is clear that the current model has superior predictive performance both in the high and low concentration range.
The present study shows a model-based individualized dosing table of treosulfan, aiming for an AUC 0-∞ of 1650 mg*h/L, which was the median exposure of our population. The recommended treosulfan dose is dependent on age and weight. An increase in treosulfan daily dose per kg until the age of 4 years can be seen, reflecting the maturation of clearance and allometry. Recently we showed that there is a relationship between treosulfan exposure and early toxicity. 18 Patients with an exposure >1650 mg*h/L have an increased risk of developing grade 2 or higher mucositis and skin toxicity. Our model could be used to establish the initial dose, prior to or during treosulfan administration to facilitate therapeutic drug monitoring and thereby prevent toxicity. HSCT. 16 More studies conducted in different disease settings are needed to establish how systemic exposure to treosulfan can influence patient outcome. Subsequently, the optimal target exposure can then be established.
We also studied a limited sampling strategy, which potentially minimizes the burden of sampling and is convenient for performing TDM in the future. Ten Brink et al. chose 2 time points at 4 and 7 hours after start of infusion, although MPE and MAPE values of the T = 1.5 and 5 hours strategy were slightly better. 17 This was done because of practical reasons to avoid sampling during infusion. In the current study, with the addition of new samples, a preference for sampling at T = 1.5 hours besides a sample after infusion was shown. This results in 100% of predicted AUC 0-∞ falling within 15% and even within 10% radius of full AUC 0-∞ . We recommend adding a sample at T = 1.5 hours to the 2-sample strategy of 4 and 7 hours after infusion, not only to increase predictive performance, but also to make to TDM protocol more robust. For instance, if in clinical practice 1 of the samples needs to be discarded due to unforeseen sampling or storage errors, one would still be able to accurately estimate the AUC 0-∞ .
Our study has some limitations. Our dataset consisted of rich (full curves) and sparse (2-point curves) data combined together, which is less useful for noncompartmental analysis. However, the current approach of population PK, using nonlinear mixed effects modelling, allows data from a variety of unbalanced sparse and rich data to be analysed. Moreover, drug levels of concomitantly given drugs (such as fludarabine and thiotepa), which might influence treosulfan PK, were not available. In addition, because treosulfan is a prodrug, the active metabolites could be of interest to incorporate in the population PK model. Danielak et al. found a weak correlation between exposure to treosulfan and the metabolite S,S-EBDM (r = 0.1681, , which could introduce a bias. However, renal function was not a significant predictor for treosulfan clearance and therefore was not of influence in our analysis.
In conclusion, a 2-compartment population PK model to describe the serum concentration-time profiles of intravenously administered treosulfan was developed. BW and age (as PMA) have been identified as significant and clinically relevant covariates influencing treosulfan PK. Treosulfan serum concentrations at 1.5, 4 and 7 hours after start of infusion can be used to accurately estimate treosulfan exposure, particularly in a TDM setting. 
